PDCD1 and hepatocellular carcinoma: Based on a successful Phase III clinical trial, the combination of the ICI atezolizumab (an anti-PD-1 antibody) with MTA bevacizumab (an anti-VEGF-A antibody) was approved as a first-line therapy for unresectable HCC [10,11].